Chandler, Arizona –September 6, 2016–The Arizona Bioindustry Association (AZBio) today announced that Arizona Governor Doug Ducey will address the life science, education, and business leaders assembled to celebrate the 11th annual AZBio Awards on September 21, 2016 at the Phoenix Convention Center.Continue reading
The Cavendish Impact Capital Life Science Fund will be formally announced at the 8th Cavendish Global Health Impact Forum taking place September 18 – 21, 2016 in Phoenix, AZ.Continue reading
The Arizona Bioindustry Association has named Mara G. Aspinall as the 2016 Jon W. McGarity Arizona Bioscience Leader of the Year in recognition of her leadership locally, nationally, and internationally in the field of biomedical diagnostics and for her roles as an active leader in Arizona’s life science community.Continue reading
A collaboration between the State Bio Associations of the Rocky Mountain Southwest, White Hat 2016 will connect investors with 32 exciting companies in the fields of Diagnostics, Therapeutics, Medical Devices, and Health IT.Continue reading
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
Latest Deal Builds on Success of MDUFA IIIContinue reading
Avery Therapeutics, Inc., a pre-clinical stage company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, has been awarded a $483k SBIR grant from the National Institutes of Health to develop manufacturing, cryopreservation, storage and reconstitution methods for Avery’s first product MyCardia™. Continue reading
The Arizona Bioindustry Association has named Marni Landry, BS, M.Ed of Paradise Valley High School as the 2016 Michael A. Cusanovich Bioscience Educator of the Year in recognition of her dedication in the classroom and her commitment to designing bioscience education programs and curriculum to help inspire and create tomorrow’s bioscience leaders.Continue reading
Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced enrollment of the first patient in a Phase II clinical trial for the treatment of cocaine dependence using its pharmaceutical cannabidiol (CBD) product candidate. The study is being conducted by Dr. Didier Jutras-Aswad, MD, at the University of Montreal Hospital Research Center (CRCHUM) and is supported by the Canadian Institutes of Health Research (CIHR) and the Company.Continue reading
Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients.